Patent ID: 9562017
Date: 2017-02-07
CPC Classifications: A61P,C07D

Claim:
1. A method for reversing, alleviating or inhibiting the progress of a cancer associated with overactivation of MEK in a mammal in need thereof, the method comprising administering to said mammal a therapeutically effective amount of a crystalline hydrogen sulfate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, wherein said hydrogen sulfate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide has an X-ray powder diffraction pattern with specific peaks at about 2-theta equal to 24.59°, 20.97°, 27.65°, 12.24°, and 17.02°.